2008
DOI: 10.1016/j.ijcard.2007.04.013
|View full text |Cite
|
Sign up to set email alerts
|

Chronic pharmacological treatment in takotsubo cardiomyopathy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
41
0
1

Year Published

2009
2009
2019
2019

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 46 publications
(43 citation statements)
references
References 21 publications
1
41
0
1
Order By: Relevance
“…TTC was rarely described in the male population, representing less than 10% of all the cases (Bybee et al, 2004;Tsuchihashi et al, 2001;Sharkey et al, 2005;Akashi et al, 2008;Kurowski et al, 2007). In this population, cardiac risk factors seem to be less described, whereas highest prevalence of anxiety or depression was reported (Kurowski et al, 2007;Vidi et al, 2009;Mudd et al 2007;Pace et al, 2011).…”
Section: Populationmentioning
confidence: 96%
See 1 more Smart Citation
“…TTC was rarely described in the male population, representing less than 10% of all the cases (Bybee et al, 2004;Tsuchihashi et al, 2001;Sharkey et al, 2005;Akashi et al, 2008;Kurowski et al, 2007). In this population, cardiac risk factors seem to be less described, whereas highest prevalence of anxiety or depression was reported (Kurowski et al, 2007;Vidi et al, 2009;Mudd et al 2007;Pace et al, 2011).…”
Section: Populationmentioning
confidence: 96%
“…This neuro-hormonal hypothesis including catecholamine excess and exaggerated stimulation of the sympathetic nervous system is supported by several studies showing that patients with TTC have supraphysiologic and higher levels of plasma catecholamines than patients with acute coronary syndrome (Wittstein et al, 2005) Moreover, several cases have been described after administration of exogenous cathecolaminergic agents such as dobutamine (Previtali et al, 2005;Abraham et al, 2009;Cherian et al, 2008;Winogradow et al, 2010). However, other studies have documented no significant elevation in plasma catecholamine levels in TTC patients (Bybee et al, 2004;Gianni et al, 2006;Tsuchihashi et al, 2001;Kawai et al, 2007;Elesber et al, 2007;Sharkey et al, 2008;Blessing et al, 2007;Sharkey et al, 2007;Fazio et al, 2008). Thus, this pathophysiological mechanism is still debated.…”
Section: Catecholamine Excessmentioning
confidence: 98%
“…Andere Autoren stehen der Applikation von β-Blockern jedoch kritisch gegenüber [2], da die potenziell unerwünschten Effekte der β-Blockade bei erhöhten Katecholaminspiegeln und nichtblockierten α-Rezeptoren miteinkalkuliert werden müs-sen [2]. In einer retrospektiven Analyse konnte für die Dauertherapie einer TK jedoch weder für Aspirin, ACE-Inhibitoren, Kalziumantagonisten noch für β-Blocker ein positiver Effekt nachgewiesen werden, sodass die Autoren keine Indikation für den Einsatz dieser Medikamente sahen [14]. Der Nachweis eines intrakardialen Thrombus macht eine systemische Antikoagulation mit Phenprocoumon oder Heparinen erforderlich.…”
Section: Verlaufunclassified
“…Although they have not shown any long-term benefit when compared to placebo, 30 ethically and physiologically, it seems reasonable to aggressively manage an acute cardiac failure. The aim should be to maintain supportive treatment in order to hopefully reduce cardiovascular morbidity and short-term mortality.…”
Section: Treatment and Follow-upmentioning
confidence: 99%